Vitrolife expands its Genomics business to the Asia Pacific region
GÖTEBORG, Sweden, Nov. 25, 2021 -- Vitrolife AB (publ) today announced that it will be expanding its distribution of genomic testing kits to the Asia Pacific region (excluding China) in accordance with the Illumina partnership agreement announced in October 2018. The expansion of the territory follows the commercial launch of EmbryoMap during Q2 of this year and requires a payment of USD 3 million (approximately SEK 27 million) to Illumina for the expanded rights. EmbryoMap has been developed by Vitrolife for use on Illumina sequencing instruments.
Vitrolife expects the acquired business to add more than SEK 50 million of revenue in 2022 and to have a marginal positive impact on earnings per share.
Gothenburg, November 25, 2021
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
The information was submitted for publication, through the agency of the contact person set out above, at 4.30 pm CET on November 25, 2021.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Vitrolife AB (publ)